RemeGen Co. Ltd. Class A RemeGen Co. Ltd. Class A

RemeGen Co. Ltd. Class A

688331

Peringkat dalam Saham #2418
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Harga Saham
$14.49
Kapitalisasi Pasar
$8.11B
Perubahan (1 hari)
2.99%
Perubahan (1 tahun)
9.18%
Negara
CN
Perdagangan RemeGen Co. Ltd. Class A (688331)

Kategori

Healthcare
Riwayat pemecahan saham untuk RemeGen Co. Ltd. Class A (688331)
Saham RemeGen Co. Ltd. Class A (simbol: 688331) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham 688331 yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham 688331.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL